ABBV

ABBVIE
D

ABBV

Arincen73/100B
294.86
USD
9.02
(3.16%)
Post Trading·295.20USD+0.34(+0.12%)
Last updated: · Delayed 15 min
Fair value398.80Plus-26%299Price 294.86499
Q4 FY2026 · Earnings report
EPS estimate 3.89Revenue estimate 18.33B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

ABBVIE stock forecast 2026–2030

Analysts' average 12-month price target for ABBVIE is 308.88, 4.8% above the current price of 294.86. Their targets range from 235.00 to 340.00.

Of the 25 firms that rated ABBVIE in the past 12 months, 21 rate it buy or strong buy, 4 hold and 0 sell or strong sell (each firm at its latest rating); on average they come to Buy.

12-month price target
308.88 USD
+4.75%

Analysts' 1-year price targets range from 235.00 to 340.00, with an average of 308.88.

Past year
1-year forecast
Strong sellStrong buy
Buy
25 ratings
Strong buy
0
Buy
21
Hold
4
Sell
0
Strong sell
0

12-month price target

Highest target340.00
Average target308.88
Lowest target235.00
Current price294.86

ABBVIE price target history

Have analysts recently raised or lowered their ABBVIE price target and rating?

See how analysts moved their price target

How analysts rate ABBVIE, month by month

21 of 25 firms rate it buy now, against 13 of 16 in December 2025.

Buy Hold Sell

Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.

Month endBuyHoldSellFirms
Nov 2026214025
Oct 2026204024
Sept 2026203023
Aug 2026203023
Jul 2026183021
Jun 2026134017
May 2026134017
Apr 2026134017
Mar 2026124016
Feb 2026124016
Jan 2026134017
Dec 2025133016

ABBVIE analyst upgrades, downgrades and price targets

The latest rating change came on 13 August 2026, when Wolfe Research upgraded ABBVIE from Peer Perform to Outperform. Its price target is 300.00. The most recent new target came from BMO Capital on 4 November 2026: 315.00.

DateFirmRatingPrice targetChangePrice then
4 Nov 2026
BMO Capital
—300.00 → 315.00+5.0%285.67
2 Nov 2026
Cantor Fitzgerald
Carter Gould
Reiterated · Overweight290.00 → 325.00+12.1%287.17

ABBVIE EPS and revenue estimates

Analysts expect ABBVIE's EPS to grow 96.6% a year until 2028. Over the last 5 years it fell 2.7% a year, and over the last 3 years it fell 29.0%.

Analysts expect ABBVIE's revenue to grow 9.1% a year until 2028, faster than over the last 5 years (6.0% a year) and the last 3 years (1.8%).

Revenue

ReportedEstimate

EPS

ReportedEstimate
Fiscal yearEPSEPS growthEPS rangeRevenueRevenue growthRevenue rangeAnalysts
FY2028 (est.) 18.00+10.4%15.14 – 21.41 79.40B+7.8%75.76B – 83.33B9
FY2027 (est.) 16.31+16.8%15.49 – 17.22 73.67B+8.9%72.03B – 75.05B16
FY2026 (est.) 13.97+39.7%13.87 – 14.17 67.67B+10.6%67.46B – 67.94B14
FY2025 10.00-1.2%— 61.16B+8.6%——
FY2024 10.12-8.9%— 56.33B+3.7%——
FY2023 11.11-19.9%— 54.32B-6.4%——
FY2022 13.87—— 58.05B———

Does ABBVIE beat earnings estimates?

On average, analysts' EPS estimate was 4.7% off the result, either way, and their revenue estimate 2.6%, over the last 12 quarters.

EPS beats
51 / 56
Revenue beats
45 / 55
Average EPS surprise, last 12
+0.1%
Since
January 2013
QuarterReport dateEPS estimateReported EPSSurpriseRevenue estimateReported revenueSurprise
Q3 FY202630 Oct 20263.733.82+2.4%17.32B17.40B+0.5%
Q2 FY202631 Jul 20263.613.65+1.1%16.80B16.99B+1.1%
Q1 FY202629 Apr 20262.592.65+2.3%14.72B15.00B+1.9%
Q4 FY20254 Feb 20262.652.71+2.3%16.41B16.62B+1.2%
Q3 FY202531 Oct 20251.771.86+5.1%15.59B15.78B+1.2%
Q2 FY202531 Jul 20252.882.97+3.1%15.03B15.42B+2.6%
Q1 FY202525 Apr 20252.382.46+3.4%12.93B13.34B+3.2%
Q4 FY202431 Jan 20252.982.16-27.5%14.83B15.10B+1.8%
Q3 FY202430 Oct 20242.923.00+2.7%14.28B14.46B+1.2%
Q2 FY202425 Jul 20242.572.65+3.1%14.02B14.46B+3.1%
Q1 FY202426 Apr 20242.262.31+2.2%11.93B12.31B+3.2%
Q4 FY20232 Feb 20242.762.79+1.1%12.98B14.30B+10.2%

ABBVIE stock price 2026–2030: scenarios

If ABBVIE's earnings keep growing at the 21.6% a year analysts expect to FY2028, it would earn about 26.64 a share in FY2030. At the P/E it has traded at over the last five years (20.9 to 96.4) that is 556.57 to 2,568.01 a share, or 1,451.23 at its average P/E of 54.5. This is arithmetic on the analysts' estimates, not a prediction.

Bull Base Bear
Fiscal yearEPSBearBaseBull
FY2026 13.97291.91761.141,346.87
FY2027 16.31340.82888.681,572.56
FY2028 18.00376.12980.721,735.42
FY2029 (extrapolated)21.90457.541,193.002,111.06
FY2030 (extrapolated)26.64556.571,451.232,568.01

Each year's EPS is the analysts' consensus to FY2028; the years after continue its 21.6% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (20.9, 54.5, 96.4).

Is ABBVIE stock undervalued or overvalued?

ABBVIE's P/E of 50.6 is around the middle of its 5-year range (18.9 to 177.5, median 51.3). It is in line with its own history. Growing ⁦96.6%⁩ a year, ABBVIE earns a P/E of 25.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 15.95, a fair value of 398.80; the price, 294.86, is ⁦26.1%⁩ below it. Its forward P/E, on the consensus for FY2026, is 21.1.

The price against its fair value
Fair value 398.80Price 294.86299.10498.50

Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 18.8 and 31.3). The price against its P/E range

Price to earnings ratio (TTM)
50.58
Five-year median P/E
51.26
Five-year P/E range
18.9 – 177.5
Forward P/E (FY2026)
21.11
PEG ratio
2.34
To the average target
+4.8%
See the full P/E history check Plus

Most undervalued US stocks

StockPriceFair valueUpside
66.390
128.2462Price 66.39185
+93.2%
101.860
195.27146Price 101.86244
+91.7%
123.790
235.44177Price 123.79294
+90.2%
200.280
359.04269Price 200.28449
+79.3%
227.150
406.28305Price 227.15508
+78.9%
159.100
284.37213Price 159.10355
+78.7%
105.320
175.76132Price 105.32220
+66.9%

Furthest below the fair value on each stock's page, updated every day.

Common questions about the ABBVIE stock forecast

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.